Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Predicting CLL Prognosis

Can sequencing identify prognostic markers?

New sequencing techniques have identified genetic markers that affect prognosis for patients with chronic lymphocytic leukemia (CLL), according to an analysis of peer-reviewed articles on clinical and prognostic factors for CLL. Among the researchers’ findings were:

• CLL patients with 17p13.1 deletion respond poorly to chemoimmunotherapy and should be treated differently

• CD38 and ZAP-70 status of mutated cells and unmutated immunoglobulin variable heavy chain gene predict adverse prognosis

• Presence of TP53 and ATM mutations predict worse prognosis, as well as inferior progression-free survival and overall survival

• TP53 mutations predict lower response to chemoimmunotherapy

• NOTCH1 and SF3B1 mutations have worse prognosis

• NOTCH1 mutation predicts lower response to standard chemoimmunotherapy

Citation: Nabhan C, Raca G, Wang L. Predicting prognosis in chronic lymphocytic leukemia in the contemporary era. [published online ahead of print May 7, 2015]. JAMA Oncol. doi:10.1001/jamaoncol.2015.0779.

This Week's Must Reads

CMS freezing of risk adjustment payments predicted to drive up insurance premiums, United States District Court Ruling Puts Risk Adjustment On Hold

If confirmed as Supreme Court justice, Kavanaugh could upend ACA, Case references, including Seven-Sky v. Holder

Software boosts accuracy of colonoscopies, Tripathi PV et al. DDW 2018 (Digestive Disease Week, 2018). Presentation 133.

Proposed fee schedule for 2019 could cut EHR hours,

Must Reads in Leukemia, Myelodysplasia, Transplantation

Added pomalidomide reduced risk of progression, death in myeloma, Richardson PG et al. ASCO 2018, Abstract 8001.

Predicting CLL Prognosis, Can sequencing identify prognostic markers?

Genes Linked to Better Outcomes in AML , SWOG study identifies mutation linked to improved survival

AML Care: Good News from SEER database, Change in early death, median survivals